Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 71, Issue 4, 2002, Pages 286-296

  Kirchheiner, Julia ^a,b,c   Brockmöller, Jürgen ^a,b   Meineke, Ingolf ^a,b   Bauer, Steffen ^a,b   Rohde, Wolfgang ^a,b   Meisel, Christian ^a,b   Roots, Ivar ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLUCOSE; INSULIN; SULFONYLUREA DERIVATIVE;

ADULT; ALLELE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RESPONSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VENOUS BLOOD;

ADULT; ALLELES; AMINO ACIDS; ANALYSIS OF VARIANCE; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BLOOD GLUCOSE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION; GENOTYPE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; POLYMORPHISM, GENETIC; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0036231580     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.122476     Document Type: Article

References (34)

1. Glibenclamide-associated hypoglycaemia: A report on 57 cases
2. Severe hypoglycaemia during glibenclamide therapy
3. Hypoglycaemia in the elderly
4. Serum glibenclamide in diabetic patients and influence of food on the kinetics and effects of glibenclamide
5. Chlorpropamide and glibenclamide serum concentrations in hospitalized patients
6. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay
7. Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus
8. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: An update
9. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs
10. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes
11. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
12. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
13. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
14. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis
15. Genetic analysis of the human cytochrome P450 CYP2C9 locus
16. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations
17. Allelic and functional variability of cytochrome P4502C9
18. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
19. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
20. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
21. Pharmacokinetics of glyburide
22. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus
23. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron 4/exon 5 G→A-splice site mutation
24. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
25. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography
26. A novel extravascular input function for the assessment of drug absorption in bioavailability studies
27. Assessment of insulin sensitivity and secretion with the labelled intravenous glucose tolerance test: Improved modelling analysis
28. Population-based modeling to demonstrate extrapancreatic effects of tolbutamide
29. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and on the insulin and glucose response in healthy volunteers
30. The new biostatistics of resampling
31. An add-in implementation of the RESAMPLING syntax under Microsoft EXCEL
32. Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes
33. Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride, and glisoxepide. II. Repeated administration in combination with glucose